Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease

In this review I summarize observations of PET and SPECT studies about cerebral blood flow and metabolic abnormalities in Alzheimer’s disease. In very early AD flow or metabolism reduces first in the posterior cingulate gyrus and precuneus. This reduction may arise from functional deafferentation caused by primary neural degeneration in the remote area of the entorhinal cortex that is the first to be pathologically affected in AD. Then medial temporal structures and parieto-temporal association cortex show flow or metabolic reduction as disease processes. The reason why flow or metabolism in medial temporal structures shows delay in starting to reduce in spite of the earliest pathological affection remains to be elucidated. It is likely that anterior cingulate gyrus is functionally involved, since attention is the first non-memory domain to be affected, before deficits in language and visuospatial functions. However few reports have described involvement in the anterior cingulate gyrus. Relationship between cerebral blood flow or metabolism and apolipoprotein E genotype has been investigated. Especially, theAPOE ε4 allele has been reported to increase risk and to lower onset age as a function of the inherited dose of the ε4 allele. Reduction of flow or metabolism in the posterior cingulate gyrus and precuneus has been reported even in presymptomatic nondemented subjects who were cognitively normal and had at least a single ε4 allele. On the contrary the relation of ε4 allele to the progression rate of AD has been controversial from neuroimaging approaches. PET and SPECT imaging has become to be quite useful for assessing therapeutical effects of newly introduced treatment for AD. Recent investigations observed significant regional flow increase after donepezil hydrochloride treatment. Most of these observations have been made by applying computer assisted analysis of three-dimensional stereotactic surface projection or statistical parametric mapping instead of a conventional regions of interest technique.

[1]  J. W. Papez A PROPOSED MECHANISM OF EMOTION , 1937 .

[2]  D. Benson,et al.  The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. , 1983, Archives of neurology.

[3]  R H Huesman,et al.  Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.

[4]  N. Foster,et al.  Alzheimer's disease , 1983, Neurology.

[5]  Luigi Mansi,et al.  Cortical abnormalities in Alzheimer's disease , 1984, Annals of neurology.

[6]  J. Haxby,et al.  Brain Imaging: Aging and Dementia , 1984 .

[7]  D. Kuhl Imaging local brain function with emission computed tomography. , 1984, Radiology.

[8]  G. V. Van Hoesen,et al.  Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.

[9]  E. Metter,et al.  Patterns of cerebral glucose utilization in depression, multiple infarct dementia, and Alzheimer's disease. , 1985, Research publications - Association for Research in Nervous and Mental Disease.

[10]  J. Haxby,et al.  Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease , 1985, Annals of neurology.

[11]  Robert P. Friedland,et al.  Alzheimer's disease: Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization , 1985, Neuroscience Letters.

[12]  W. Jagust,et al.  Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia. , 1985, The American journal of psychiatry.

[13]  J. Haxby,et al.  Positron emission tomography in Alzheimer's disease , 1986, Neurology.

[14]  B. L. Beattie,et al.  Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  G. di Chiro,et al.  Dominantly inherited Alzheimer's disease: cerebral glucose metabolism. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[16]  J. Becker,et al.  Cognitive deficits and clinical diagnosis of Alzheimer's disease , 1987, Neurology.

[17]  J. Growdon,et al.  Single photon emission computed tomography in Alzheimer's disease. Abnormal iofetamine I 123 uptake reflects dementia severity. , 1988, Archives of neurology.

[18]  J. Haxby,et al.  Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. , 1990, Journal of psychiatric research.

[19]  B. L. Beattie,et al.  18Fluorodeoxyglucose Positron Emission Tomography Studies in Presumed Alzheimer Cases, Including 13 Serial Scans , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[20]  J. Haxby,et al.  Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. , 1990, Archives of neurology.

[21]  Karl Herholz,et al.  Criteria for the Diagnosis of Alzheimer's Disease with Positron Emission Tomography , 1990 .

[22]  Functional Brain Imaging and Alzheimer-Type Dementia , 1991, Alzheimer disease and associated disorders.

[23]  E K Warrington,et al.  Selective impairment of memory and visual perception in splenial tumours. , 1991, Brain : a journal of neurology.

[24]  K. Herholz,et al.  Abnormalities of Energy Metabolism in Alzheimer's Disease Studied with PET a , 1991, Annals of the New York Academy of Sciences.

[25]  G Blomqvist,et al.  Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[26]  M. Corbetta,et al.  Selective and divided attention during visual discriminations of shape, color, and speed: functional anatomy by positron emission tomography , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  K. Herholz,et al.  Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type , 1992, Neurobiology of Aging.

[28]  G D Pearlson,et al.  Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. , 1992, Archives of general psychiatry.

[29]  S Minoshima,et al.  An automated method for rotational correction and centering of three-dimensional functional brain images. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  N Butters,et al.  Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. , 1992, Archives of neurology.

[31]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[32]  M. Mintun,et al.  Automated detection of the intercommissural line for stereotactic localization of functional brain images. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[34]  T. Iwatsubo,et al.  Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease , 1994, The Lancet.

[35]  K. Fukushi,et al.  Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. , 1994, Nuclear medicine and biology.

[36]  Satoshi Minoshima,et al.  Posterior cingulate cortex in Alzheimer's disease , 1994, The Lancet.

[37]  K. Weisgraber Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.

[38]  R. Koeppe,et al.  Anatomic standardization: linear scaling and nonlinear warping of functional brain images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Giovanni B. Frisoni,et al.  Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease , 1995 .

[40]  P M Grasby,et al.  Brain systems for encoding and retrieval of auditory-verbal memory. An in vivo study in humans. , 1995, Brain : a journal of neurology.

[41]  H. Soininen,et al.  Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ϵ4 allele , 1995, Neurology.

[42]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[43]  A. Smith,et al.  Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease , 1995, Neuroscience.

[44]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[45]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[47]  N. Foster,et al.  Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.

[48]  H. Hoshi,et al.  High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  R. Albin,et al.  Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.

[50]  K. Ishii,et al.  Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  H. Soininen,et al.  SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[52]  B T Hyman,et al.  Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.

[53]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[54]  S. Corkin,et al.  Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease , 1996, Neurology.

[55]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[56]  D J Wyper,et al.  Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. , 1996, Journal of psychiatric research.

[57]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[58]  C. Frith Principles and methods , 1997 .

[59]  Akira Homma,et al.  Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E ϵ4 allele , 1997, Neuroscience Letters.

[60]  T G Turkington,et al.  Selective and divided visual attention: Age‐related changes in regional cerebral blood flow measured by H215O PET , 1997, Human brain mapping.

[61]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[62]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[63]  Yaakov Stern,et al.  The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's disease , 1997, Annals of neurology.

[64]  A. Asaka,et al.  Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians. , 1997, Human heredity.

[65]  K. Ishii,et al.  Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  L. Wahlund,et al.  MRI-guided SPECT-measurements of medial temporal lobe blood flow in Alzheimer's disease , 1997, Psychiatry Research: Neuroimaging.

[67]  S. Scheff,et al.  Time Course of Changes in Lactate and Free Fatty Acids after Experimental Brain Injury and Relationship to Morphologic Damage , 1997, Experimental Neurology.

[68]  E. Corder,et al.  No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. , 1997, Archives of neurology.

[69]  K. Ishii,et al.  Lack of Association of Apolipoprotein E ε4 Allele Dose with Cerebral Glucose Metabolism in Alzheimer Disease , 1998 .

[70]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[71]  Jonathan D. Cohen,et al.  Reproducibility of fMRI Results across Four Institutions Using a Spatial Working Memory Task , 1998, NeuroImage.

[72]  J. Baron,et al.  The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. , 1998, Brain : a journal of neurology.

[73]  Daniel B Hier,et al.  Visual Form of Alzheimer's Disease and Its Response to Anticholinesterase Therapy , 1998, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[74]  K. Ishii,et al.  Paradoxical hippocampus perfusion in mild-to-moderate Alzheimer's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  H. Soininen,et al.  Longitudinal SPECT study in Alzheimer’s disease: relation to apolipoprotein E polymorphism , 1998, Journal of neurology, neurosurgery, and psychiatry.

[76]  G. Alexander,et al.  Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease , 1998, Neurology.

[77]  Steven D. Edland,et al.  Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.

[78]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[79]  M. Macavoy,et al.  Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease. , 1998, Archives of neurology.

[80]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[81]  B L Holman,et al.  Preclinical prediction of Alzheimer's disease using SPECT , 1998, Neurology.

[82]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[83]  S. Minoshima,et al.  In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.

[84]  A. Hofman,et al.  Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study , 1999, Journal of Neurology.

[85]  G Mariani,et al.  99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: a correlative study. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  J. Baron,et al.  Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. , 1999, Brain : a journal of neurology.

[87]  J. Hodges,et al.  Attention and executive deficits in Alzheimer's disease. A critical review. , 1999, Brain : a journal of neurology.

[88]  J. Wegiel,et al.  MRI of entorhinal cortex in mild Alzheimer's disease , 1999, The Lancet.

[89]  A W Toga,et al.  Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[90]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[91]  R T Staff,et al.  Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy , 2000, Nuclear medicine communications.

[92]  K. Beyreuther,et al.  Prospects for pharmacological intervention in Alzheimer disease. , 2000, Archives of neurology.

[93]  S. Tanada,et al.  Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study , 2000, Annals of neurology.

[94]  K Ball,et al.  Visual attention impairments in Alzheimer’s disease , 2000, Neurology.

[95]  R. Koeppe,et al.  Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex , 2000, Annals of neurology.

[96]  F. Craik,et al.  The Effect of Divided Attention on Encoding and Retrieval in Episodic Memory Revealed by Positron Emission Tomography , 2000, Journal of Cognitive Neuroscience.

[97]  T. Ohnishi,et al.  Longitudinal Evaluation of Early Alzheimer's Disease Using Brain Perfusion Spect the Recruitment Was For , 2000 .